High on-treatment platelet reactivity (HRPR) is associated with a two- to ninefold increased risk of recurrent ischemic events among patients receiving dual antiplatelet therapy (DAPT) for coronary artery disease. However, its determinants are still poorly understood. The aim of the present study was to assess the impact of mean platelet volume (MPV) on platelet reactivity in patients receiving DAPT after an acute coronary syndrome or PCI.
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor
ROLLA, Roberta;BELLOMO, Giorgio;MARINO, Paolo;DE LUCA, GIUSEPPE
2015-01-01
Abstract
High on-treatment platelet reactivity (HRPR) is associated with a two- to ninefold increased risk of recurrent ischemic events among patients receiving dual antiplatelet therapy (DAPT) for coronary artery disease. However, its determinants are still poorly understood. The aim of the present study was to assess the impact of mean platelet volume (MPV) on platelet reactivity in patients receiving DAPT after an acute coronary syndrome or PCI.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
60.mvp aggreg EOOP.pdf
file disponibile agli utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
DRM non definito
Dimensione
5.97 MB
Formato
Adobe PDF
|
5.97 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
